3.435USD-3.78%Mkt Cap: 32.08M USDP/E: —Last update: 2026-05-26
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap32.08M USD
Enterprise Value8.87M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-18.21M USD
Revenue/Share—
Last Price3.435 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.57
PEG—
EV/EBITDA-0.30
EV/Revenue—
P/S—
P/B1.61
EPS (TTM)-0.27
EPS (Forward)-2.28
52W Range
2.7502% of range43.65
52W High43.65 USD
52W Low2.750 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-86.96%
ROA-56.79%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.50M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-36.06%
Net Debt-24.81M USD
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.01
Current Ratio2.25
Quick Ratio2.22
Book Value/Sh2.233 USD
Cash/Share2.663 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:3
Split DateApr 16, 2025
Analyst Consensus
Rating2.1 (Buy)
Target (Mean)8.167 USD
Target Range3.000 USD – 15.00 USD
# Analysts6
Ownership
Shares Out.9.38M
Float6.46M
Insiders34.64%
Institutions28.93%
Short Interest
Short Ratio9.9d
Short % Float5.45%
Short % Out.5.43%
Shares Short508.94K
Short (prev mo.)653.88K
Technical
SMA 503.430 (+0.1%)
SMA 20010.67 (-67.8%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)43.93K
Avg Vol (10d)41.90K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—